Fujifilm completes acquisition of dedicated cell therapy

TOKYO, April 04, 2022 (GLOBE NEWSWIRE) — FUJIFILM Corporation (President and Chief Executive Officer, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for $100 million. The facility located in Thousand Oaks, California will be operated as part of the global network of FUJIFILM Diosynth Biotechnologies, which is a subsidiary of FUJIFILM Corporation and a world-leading contract development and manufacturing organization (CDMO).

The 90,000 square foot facility is easily expandable to add capacity and has the flexibility to produce clinical and commercial cell therapies, including allogeneic T cell and CAR T immunotherapies. FUJIFILM Diosynth Biotechnologies will retain 134 manufacturing employees and quality on the site.

Under a long-term manufacturing and services agreement, FUJIFILM Diosynth Biotechnologies will support the production of Atara’s promising allogeneic cell therapies at the clinical and commercial stage at the site, including tabelecleucel (tab-cel®), currently in phase 3 clinical development and under review to support registration in Europe, for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV + PTLD).

“FUJIFILM Corporation has invested more than $5.5 billion to develop the Bio CDMO business unit to provide our customers with long-term support across a full range of manufacturing modalities and scales,” said Takatoshi Ishikawa. , Senior Executive Vice President, General Head of Bio CDMO Division, FUJIFILM Corporation. “With the addition of the dedicated site in California, Fujifilm continues to build for the future to meet the growing need for advanced therapies globally.”

“We are delighted to welcome 134 new members to the FUJIFILM Diosynth Biotechnologies family today with the acquisition of the dedicated cell therapy manufacturing facility. Developing our world-class talent and knowledge in manufacturing advanced therapies is critical to our continued success in supporting our partners in advancing the medicines of tomorrow,” added Martin Meeson, CEO of FUJIFILM Diosynth Biotechnologies. “With the talent of the new site, its strategic location on the west coast and the potential for future capacity growth, we are confident that we will help our partners deliver T-cell and CAR-T therapies to bring hope. to patients.”

The facility is the newest addition to FUJIFILM Diosynth Biotechnologies’ global portfolio of manufacturing sites, which includes facilities in College Station, Texas, USA, Research Triangle Park, North Carolina, USA, Teesside, UK Kingdom and Hillerød, Denmark.

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a global leader in contract development and manufacturing (CDMO) with experience in the development and manufacturing of biologics, vaccines and advanced therapies. FUJIFILM Diosynth Biotechnologies has existing sites in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerød, Denmark. The company is currently constructing new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has more than thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide range of systems microbial, mammalian and host/virus. The company offers a comprehensive list of services ranging from cell line development using its proprietary pAVEway™ and Apollo™X microbial cell line systems to process development, analytical development, clinical and regulatory approved commercial manufacturing. FDA. Mitsubishi Corporation is a 20% shareholder of the FUJIFILM Diosynth Biotechnologies sites in the United Kingdom, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas. For more information, visit: www.fujifilmdiosynth.com.

About FUJIFILM Corporation

FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting-edge solutions to a wide range of global industries by leveraging its deep knowledge and core technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to various fields, including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the fiscal year ended March 31, 2021, the company had worldwide revenue of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: https://www.fujifilmholdings.com.



        

Comments are closed.